AvevoRx Earns Third Consecutive Triad Fast 50 Recognition for Growth

AvevoRx Secures Third Consecutive Triad Fast 50 Ranking Amid Expansion

AvevoRx, a national provider of specialty infusion pharmacy services, has been recognized for its rapid growth, securing the No. 2 spot in the 2026 Triad Business Journal Fast 50 Awards. This marks the third consecutive year the Greensboro-based company has appeared on the list of the fastest-growing privately held companies in North Carolina's Triad region. The recognition follows a period of significant national expansion driven by investments in pharmacy infrastructure, strategic acquisitions, and expanded patient support programs.

The company's growth has enabled it to serve approximately 97 percent of the U.S. population. AvevoRx was also ranked No. 401 overall on the 2026 Inc. 5000 list of America's fastest-growing private companies. Key expansion initiatives include the establishment of new pharmacy operations in Atlanta and Austin, the acquisition of Sunrise Rx on Long Island, and broadening relationships with payers to improve patient access to therapies.

"Being recognized among the Triad's fastest-growing companies for a third consecutive year is especially meaningful because Greensboro is our home," said Lauren Pumphrey, co-founder of AvevoRx. "Our growth has been significant, but what matters most is what that growth allows us to do: reach more patients, expand access to important therapies and continue investing in the people, infrastructure and clinical capabilities that support a truly personalized model of care."

Robin Johnson, chief financial officer at AvevoRx, stated that the company's growth strategy focuses on long-term investments in its people, pharmacy infrastructure, and patient experience. This approach allows for responsible scaling without compromising the personalized care model that distinguishes AvevoRx, which has evolved from a startup into a national specialty infusion provider.